IBRANCE® (palbociclib) is switching from capsules to tablets



Beginning in October, you will notice a change with your IBRANCE treatment. It will be changing from its current capsule formulation to tablets

As part of Pfizer's ongoing commitment to patients, Pfizer are changing the current capsule formulation of IBRANCE to tablets. The tablet formulation is intended to better support patient needs and preferences. The timing of the transition may vary for individuals, as pharmacies work through their current stock. The transition should be smooth, with you seeing no impact on the availability of your next IBRANCE prescription.

Important Facts

There is no change to the active ingredient of IBRANCE, which is palbociclib. This means that IBRANCE will continue to work in the same way to treat your breast cancer[1]

IBRANCE dosing remains once daily, with available doses of 125 mg, 100 mg and 75 mg. If you previously took 125 mg capsules, you will be prescribed 125 mg tablets.[1]

The dosing schedule of IBRANCE will remain the same; you should continue to take IBRANCE on a 3-week on, 1 week off schedule[1]

The new IBRANCE tablets can be taken with or without food and do not contain lactose or gelatine[1]

Monitoring requirements for the new IBRANCE tablets will remain the same[1]

What is changing with IBRANCE?

	Current capsules Not shown to actual size	Tablets Not shown to actual size
	 125 mg 100 mg 75 mg	 125 mg 100 mg 75 mg
Administration	Must be taken with food	May be taken with or without food[1]
Structure	Contains lactose (dairy) and gelatine	Does not contain lactose (dairy) or gelatine[1]
Coating	Gelatine coating on capsule	Film-coated tablet[1]

Why is IBRANCE changing?

This change is designed to better support you by:

Improving convenience
You can take IBRANCE tablets with or without food

Helping track your medication schedule
IBRANCE tablets come in weekly blister packs that are designed to help you track your treatment cycles

Addressing dietary concerns
IBRANCE tablets do not contain lactose (dairy) or gelatine

It is important to note that there is no change to the active ingredient (palbociclib), available dosage strengths (125 mg, 100 mg and 75 mg), or dosing schedule.[1]

You don't need to do anything and no changes are required to the way you take IBRANCE. If you have any concerns please reach out to your healthcare team.

IBRANCE® (palbociclib, 75 mg, 100 mg and 125 mg) Capsules and Tablets. IBRANCE (palbociclib) is a funded prescription medicine used to treat HR+, HER2- advanced breast cancer taken in combination with an aromatase inhibitor or fulvestrant. IBRANCE has risks and benefits. Do not take IBRANCE if you are allergic to palbociclib or any of the other ingredients in IBRANCE capsules or IBRANCE tablets. Caution is needed if you are premenopausal or perimenopausal, have or have had abnormal blood test results, respiratory infections or problems with your lungs, problems with your liver or kidneys, are lactose intolerant, are pregnant or planning to become pregnant or are breastfeeding. Tell your doctor if you are taking any other medicines. Common side effects include infection, abnormal blood test results, tiredness, feeling sick or vomiting, diarrhoea, sore mouth, lips or tongue, hair loss, loss of appetite, nose bleed, skin rash, change in sense of taste, blurred vision, increased tearing or dry eyes, shortness of breath, bleeding or bruising more easily than usual. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. Ask your doctor if IBRANCE is right for you. Use strictly as directed. Contains 75 mg, 100 mg or 125 mg of palbociclib. IBRANCE is funded. A pharmacy charge and normal doctor's fees apply for all prescriptions. Further information on IBRANCE is available from Medsafe www.medsafe.govt.nz or Pfizer New Zealand Limited, Auckland, www.pfizer.co.nz Ph. 0800 736 363. V10721

Reference: 1. Ibrance Data Sheet.

IBRANCE® palbociclib